149 related articles for article (PubMed ID: 35596071)
21. Moving the Needle on Alzheimer's Disease with an Anti-Oligomer Antibody.
Gandy S; Ehrlich ME
N Engl J Med; 2023 Jan; 388(1):80-81. PubMed ID: 36599066
[No Abstract] [Full Text] [Related]
22. The amyloid hypothesis revisited: are monoclonal antibodies truly effective?
Ross J; Hasan I
Inflammopharmacology; 2023 Jun; 31(3):1027-1028. PubMed ID: 36995576
[No Abstract] [Full Text] [Related]
23. Medicare and Amyloid PET Imaging: The Battle Over Evidence.
Maschke KJ; Gusmano MK
J Aging Soc Policy; 2017; 29(2):105-122. PubMed ID: 27285978
[TBL] [Abstract][Full Text] [Related]
24. CMS Will Cover Alzheimer Drugs With Traditional FDA Approval.
Harris E
JAMA; 2023 Jul; 330(1):14. PubMed ID: 37314825
[No Abstract] [Full Text] [Related]
25. Amyloid beta peptide immunotherapy in Alzheimer disease.
Delrieu J; Ousset PJ; Voisin T; Vellas B
Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
[TBL] [Abstract][Full Text] [Related]
26. Life imitates art: anti-amyloid antibodies and inflammatory cerebral amyloid angiopathy.
Greenberg SM; Frosch MP
Neurology; 2011 Mar; 76(9):772-3. PubMed ID: 21357829
[No Abstract] [Full Text] [Related]
27. The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes.
Kepp KP; Sensi SL; Johnsen KB; Barrio JR; Høilund-Carlsen PF; Neve RL; Alavi A; Herrup K; Perry G; Robakis NK; Vissel B; Espay AJ
J Alzheimers Dis; 2023; 94(2):497-507. PubMed ID: 37334596
[TBL] [Abstract][Full Text] [Related]
28. SNMMI Reacts to CMS Coverage Decision.
J Nucl Med; 2022 Mar; 63(3):12N. PubMed ID: 35232885
[No Abstract] [Full Text] [Related]
29. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
[TBL] [Abstract][Full Text] [Related]
30. The Centers for Medicare and Medicaid Services (CMS) COVID-19 Brief: Unsettling Racial and Ethnic Health Disparities.
Adashi EY; Gruppuso PA
J Am Board Fam Med; 2021 Feb; 34(Suppl):S13-S15. PubMed ID: 33622810
[TBL] [Abstract][Full Text] [Related]
31. Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease.
Solomon B
Drugs Today (Barc); 2007 May; 43(5):333-42. PubMed ID: 17724499
[TBL] [Abstract][Full Text] [Related]
32. Adapting prescribing criteria for amyloid-targeted antibodies for adults with Down syndrome.
Hillerstrom H; Fisher R; Janicki MP; Chicoine B; Christian BT; Esbensen A; Esralew L; Fortea J; Hartley S; Hassenstab J; Keller SM; Krinsky-McHale S; Lai F; Levin J; McCarron M; McDade E; Rebillat AS; Rosas HD; Silverman W; Strydom A; Zaman SH; Zetterberg H
Alzheimers Dement; 2024 May; 20(5):3649-3656. PubMed ID: 38480678
[TBL] [Abstract][Full Text] [Related]
33. Amyloid Cascade into Clarity.
Weitz TM; Town T
Immunity; 2016 Oct; 45(4):717-718. PubMed ID: 27760336
[TBL] [Abstract][Full Text] [Related]
34. Identification of amyloid antibodies for Alzheimer disease - immunotherapy.
Huwait EA; Baghallab IM; Glabe CG; Abulnaja KO; Kumosani TA; Moselhy SS
Arch Physiol Biochem; 2022 Oct; 128(5):1275-1282. PubMed ID: 32449861
[TBL] [Abstract][Full Text] [Related]
35. Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide.
Cehlar O; Skrabana R; Revajova V; Novak M
Bratisl Lek Listy; 2018; 119(4):201-204. PubMed ID: 29663816
[TBL] [Abstract][Full Text] [Related]
36. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
Rygiel K
Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
[TBL] [Abstract][Full Text] [Related]
37. Value in development of a TAPIR-like mouse monoclonal antibody to Abeta.
Sambamurti K; Pappolla MA; Jagannatha Rao KS
J Alzheimers Dis; 2008 Jun; 14(2):175-7. PubMed ID: 18663823
[No Abstract] [Full Text] [Related]
38. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
[TBL] [Abstract][Full Text] [Related]
39. Development and characterization of a TAPIR-like mouse monoclonal antibody to amyloid-beta.
Wang J; Hara H; Makifuchi T; Tabira T
J Alzheimers Dis; 2008 Jun; 14(2):161-73. PubMed ID: 18560128
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
